Ocrevus 300 mg concentrate for solution for infusion clinical trials
4 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic use (Phase IV)
A Phase IV, Multicenter, Open-Label Study Evaluating B-Cell Levels in Infants Potentially Exposed to Ocrelizumab During Pregnancy – The MINORE Study
This study looks at babies born to mothers who received Ocrevus for MS during pregnancy. It checks babies' immune cells and health to understand the effects of the treatment on them. It's an important step for helping doctors and parents make informed decisions.
For: Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS) [in line with the locally approved indications]Spain · Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Single Arm, Open Label Multicentre Extension Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-La Roche Sponsored Ocrelizumab Phase IIIb/IV Clinical Trial
This study looks at how well a medicine called ocrelizumab works and if it's safe for people with multiple sclerosis (MS). It's for patients who have already been in similar studies with the same medicine.
For: Multiple sclerosis (MS)Hungary · Norway · Croatia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Radiological and Clinical Effects of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab in Patients with Multiple Sclerosis
This study is looking at a new way to give a medicine called Ocrevus to people with Multiple Sclerosis (MS). Instead of an IV drip, it might be given as a shot under the skin. We want to see if it works just as well and is safe.
For: Multiple Sclerosis (MS)Spain · Czechia · Poland - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Randomized, Multicenter Study of KYV101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis (KYSA-7)
This study is testing a new type of cell therapy called KYV101 for people with serious forms of multiple sclerosis (MS) that are getting worse. It compares this new treatment with existing MS medications to see how well it works and if it's safe.
For: Primary or Secondary Progressive Multiple SclerosisGermany · Italy · Belgium